nach oben

Clinical Rheumatology

Erschienen in:

11.07.2020 | COVID-19 | Review Article Zur Zeit gratis

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

verfasst von: Sakir Ahmed, Olena Zimba, Armen Yuri Gasparyan

Erschienen in: Clinical Rheumatology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

The pathogenesis of Coronavirus disease 2019 (COVID-19) is gradually being comprehended. A high number of thrombotic episodes are reported, along with the mortality benefits of heparin. COVID-19 can be viewed as a prothrombotic disease. We overviewed the available evidence to explore this possibility. We identified various histopathology reports and clinical case series reporting thromboses in COVID-19. Also, multiple coagulation markers support this. COVID-19 can be regarded as a risk factor for thrombosis. Applying the principles of Virchow’s triad, we described abnormalities in the vascular endothelium, altered blood flow, and platelet function abnormalities that lead to venous and arterial thromboses in COVID-19. Endothelial dysfunction, activation of the renin-angiotensin-aldosterone system (RAAS) with the release of procoagulant plasminogen activator inhibitor (PAI-1), and hyperimmune response with activated platelets seem to be significant contributors to thrombogenesis in COVID-19. Stratifying risk of COVID-19 thromboses should be based on age, presence of comorbidities, D-dimer, CT scoring, and various blood cell ratios. Isolated heparin therapy may not be sufficient to combat thrombosis in this disease. There is an urgent need to explore newer avenues like activated protein C, PAI-1 antagonists, and tissue plasminogen activators (tPA). These should be augmented with therapies targeting RAAS, antiplatelet drugs, repurposed antiinflammatory, and antirheumatic drugs.

Key Points

• Venous and arterial thromboses in COVID-19 can be viewed through the prism of Virchow’s triad.

• Endothelial dysfunction, platelet activation, hyperviscosity, and blood flow abnormalities due to hypoxia, immune reactions, and hypercoagulability lead to thrombogenesis in COVID-19.

• There is an urgent need to stratify COVID-19 patients at risk for thrombosis using age, comorbidities, D-dimer, and CT scoring.

• Patients with COVID-19 at high risk for thrombosis should be put on high dose heparin therapy.

COVID-19 situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 3 Jun 2020

Cohen J, Normile D (2020) New SARS-like virus in China triggers alarm. Science 367:234–235. https://doi.org/10.1126/science.367.6475.234CrossRefPubMed

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRef

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRef

Garaci F, Di Giuliano F, Picchi E et al (2020) Venous cerebral thrombosis in COVID-19 patient. J Neurol Sci 414:116871. https://doi.org/10.1016/j.jns.2020.116871CrossRefPubMedPubMedCentral

Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368:473–474. https://doi.org/10.1126/science.abb8925CrossRefPubMed

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

Paessler S, Walker DH (2013) Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 8:411–440. https://doi.org/10.1146/annurev-pathol-020712-164041CrossRefPubMed

Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VEA, Meijers JCM, Brandjes DPM, van Gorp ECM (2012) Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 84:1680–1696. https://doi.org/10.1002/jmv.23354CrossRefPubMedPubMedCentral

10.

Smeeth L, Cook C, Thomas S et al (2006) Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet Lond 367:1075–1079. https://doi.org/10.1016/S0140-6736(06)68474-2CrossRef

11.

Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M (2020) Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, Clinicopathologic Case Series. Ann Intern Med. https://doi.org/10.7326/M20-2566

12.

Tang N, Bai H, Chen X et al (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. https://doi.org/10.1111/jth.14817

13.

Wang Z, Du Z, Zhu F (2020) Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 164:108214. https://doi.org/10.1016/j.diabres.2020.108214CrossRefPubMedPubMedCentral

14.

Beloncle FM, Pavlovsky B, Desprez C, Fage N, Olivier PY, Asfar P, Richard JC, Mercat A (2020) Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome. Ann Intensive Care 10:55. https://doi.org/10.1186/s13613-020-00675-7CrossRefPubMedPubMedCentral

15.

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D (2020) COVID-19 does not Lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 201:1299–1300. https://doi.org/10.1164/rccm.202003-0817LECrossRefPubMedPubMedCentral

16.

Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LRG, Mewburn JD, Parlow JL, Archer SL (2017) Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest 151:181–192. https://doi.org/10.1016/j.chest.2016.09.001CrossRefPubMed

17.

Sklar MC, Patel BK, Beitler JR, Piraino T, Goligher E (2019) Optimal ventilator strategies in acute respiratory distress syndrome. Semin Respir Crit Care Med 40:81–93. https://doi.org/10.1055/s-0039-1683896CrossRefPubMedPubMedCentral

18.

Fan H, Zhang L, Huang B, Zhu M, Zhou Y, Zhang H, Tao X, Cheng S, Yu W, Zhu L, Chen J (2020) Cardiac injuries in patients with coronavirus disease 2019: not to be ignored. Int J Infect Dis 96:294–297. https://doi.org/10.1016/j.ijid.2020.05.024CrossRefPubMedPubMedCentral

19.

Vrsalovic M, Vrsalovic Presecki A (2020) Cardiac troponins predict mortality in patients with COVID-19: a meta-analysis of adjusted risk estimates. J Inf Secur. https://doi.org/10.1016/j.jinf.2020.05.022

20.

Zhou R (2020) Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients? Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa392

21.

Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, García-García A, García-Fernández-Bravo I, Ji Z, de-Miguel-Diez J, Álvarez-Sala-Walther LA, del-Toro-Cervera J, Galeano-Valle F (2020) Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 192:23–26. https://doi.org/10.1016/j.thromres.2020.05.018CrossRefPubMedPubMedCentral

22.

Stoneham SM, Milne KM, Nuttal E, Frew GH, Sturrock BR, Sivaloganathan H, Ladikou EE, Drage S, Phillips B, Chevassut TJT, Eziefula AC (2020) Thrombotic risk in COVID-19: a case series and case-control study. Clin Med Lond:clinmed.2020–clinmed.0228. https://doi.org/10.7861/clinmed.2020-0228

23.

(2020) Analysis on 54 mortality cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020. J Korean Med Sci 35. https://doi.org/10.3346/jkms.2020.35.e132

24.

Galván Casas C, Català A, Carretero Hernández G et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. https://doi.org/10.1111/bjd.19163

25.

Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D (2020) SARS-CoV-2-induced Kawasaki-like Hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics:e20201711. https://doi.org/10.1542/peds.2020-1711

26.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

27.

Salerno M, Sessa F, Piscopo A et al (2020) No autopsies on COVID-19 deaths: a missed opportunity and the lockdown of science. J Clin Med 9. https://doi.org/10.3390/jcm9051472

28.

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY (2020) Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 15:700–704. https://doi.org/10.1016/j.jtho.2020.02.010CrossRefPubMedPubMedCentral

29.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420–422. https://doi.org/10.1016/S2213-2600(20)30076-XCrossRefPubMedPubMedCentral

30.

Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S (2020) Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-2003

31.

Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S (2020) COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol 153:725–733. https://doi.org/10.1093/ajcp/aqaa062CrossRefPubMed

32.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007CrossRefPubMedPubMedCentral

33.

Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY (2020) Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 33:1007–1014. https://doi.org/10.1038/s41379-020-0536-xCrossRefPubMedPubMedCentral

34.

Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98:219–227. https://doi.org/10.1016/j.kint.2020.04.003CrossRefPubMedPubMedCentral

35.

Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, Malheiros DMAC, de Oliveira EP, Theodoro Filho J, Pinho JRR, Soares Gomes-Gouvêa M, Salles APM, de Oliveira IRS, Mauad T, do Nascimento Saldiva PH, Dolhnikoff M (2020) Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology. https://doi.org/10.1111/his.14160

36.

Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN (2020) Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol 46:151530. https://doi.org/10.1016/j.anndiagpath.2020.151530CrossRefPubMedPubMedCentral

37.

Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, Tzankov A (2020) Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. https://doi.org/10.1111/his.14134

38.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2015432

39.

Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, Lombardi A, Blasi F, Mosca F, Peyvandi F (2020) Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res 191:36–37. https://doi.org/10.1016/j.thromres.2020.04.022CrossRefPubMedPubMedCentral

40.

Ahmed I, Azhar A, Eltaweel N, Tan BK (2020) First Covid-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol 190:e37–e38. https://doi.org/10.1111/bjh.16849CrossRefPubMed

41.

Baergen RN, Heller DS (2020) Placental pathology in Covid-19 positive mothers: preliminary findings. Pediatr Dev Pathol 23:177–180. https://doi.org/10.1177/1093526620925569CrossRefPubMedPubMedCentral

42.

Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bnà C, Vogrig A (2020) Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. https://doi.org/10.1007/s00415-020-09885-2

43.

Yaghi S, Ishida K, Torres J et al (2020) SARS2-CoV-2 and stroke in a New York healthcare system. Stroke:STROKEAHA120030335. https://doi.org/10.1161/STROKEAHA.120.030335

44.

Tunç A, Ünlübaş Y, Alemdar M, Akyüz E (2020) Coexistence of COVID-19 and acute ischemic stroke report of four cases. J Clin Neurosci. https://doi.org/10.1016/j.jocn.2020.05.018

45.

Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, Humphries F, Jäger HR, Losseff NA, Perry RJ, Shah S, Simister RJ, Turner D, Chandratheva A, Werring DJ (2020) Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry:jnnp-2020-323586. https://doi.org/10.1136/jnnp-2020-323586

46.

Kihira S, Schefflein J, Chung M et al (2020) Incidental COVID-19 related lung apical findings on stroke CTA during the COVID-19 pandemic. J Neurointerv Surg. https://doi.org/10.1136/neurintsurg-2020-016188

47.

Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, Glaser A, Elsayegh D (2020) COVID-19 presenting as stroke. Brain Behav Immun 87:115–119. https://doi.org/10.1016/j.bbi.2020.04.077CrossRefPubMedPubMedCentral

48.

Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Alexia B, Sandri MT, Barco S, Humanitas COVID-19 Task Force (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024CrossRefPubMedPubMedCentral

49.

Llitjos J-F, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. https://doi.org/10.1111/jth.14869

50.

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14888

51.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 191:148–150. https://doi.org/10.1016/j.thromres.2020.04.041CrossRefPubMedPubMedCentral

52.

Poyiadji N, Cormier P, Patel PY et al (2020) Acute pulmonary embolism and COVID-19. Radiology 201955:201955. https://doi.org/10.1148/radiol.2020201955CrossRef

53.

Helms J, Tacquard C, Severac F et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46:1089–1098. https://doi.org/10.1007/s00134-020-06062-xCrossRefPubMedPubMedCentral

54.

Grillet F, Behr J, Calame P et al (2020) Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology 201544. https://doi.org/10.1148/radiol.2020201544

55.

Bompard F, Monnier H, Saab I et al (2020) Pulmonary embolism in patients with Covid-19 pneumonia. Eur Respir J. https://doi.org/10.1183/13993003.01365-2020

56.

Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, Parnell R, Awwad C, Patel D (2020) Pulmonary embolism and increased levels of D-dimer in patients with Coronavirus disease. Emerg Infect Dis 26. https://doi.org/10.3201/eid2608.201477

57.

Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, Schneider F, Labani A, Bilbault P, Moliere S, Leyendecker P, Roy C, Ohana M (2020) Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology 201561:201561. https://doi.org/10.1148/radiol.2020201561CrossRef

58.

Lim W, Meade M, Lauzier F et al (2015) Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med 43:401–410. https://doi.org/10.1097/CCM.0000000000000713CrossRefPubMed

59.

Tee A, Wong A, Yusuff T et al (2020) Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient. Intensive Care Med. https://doi.org/10.1007/s00134-020-06085-4

60.

Peng Q-Y, Wang X-T, Zhang L-N, Chinese Critical Care Ultrasound Study Group (CCUSG) (2020) Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. Intensive Care Med 46:849–850. https://doi.org/10.1007/s00134-020-05996-6CrossRefPubMed

61.

Lurie JM, Png CYM, Subramaniam S, Chen S, Chapman E, Aboubakr A, Marin M, Faries P, Ting W (2019) Virchow’s triad in “silent” deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 7:640–645. https://doi.org/10.1016/j.jvsv.2019.02.011CrossRefPubMed

62.

Alturki N, Alkahtani M, Daghistani M, Alyafi T, Khairy S, Ashi M, Aljuffri A (2019) Incidence and risk factors for deep vein thrombosis among pediatric burn patients. Burns 45:560–566. https://doi.org/10.1016/j.burns.2018.09.032CrossRefPubMed

63.

Watson T, Shantsila E, Lip GYH (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet Lond 373:155–166. https://doi.org/10.1016/S0140-6736(09)60040-4CrossRef

64.

Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, Gupta M (2018) Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis 276:98–108. https://doi.org/10.1016/j.atherosclerosis.2018.07.014CrossRefPubMed

65.

Stoll G, Nieswandt B (2019) Thrombo-inflammation in acute ischaemic stroke - implications for treatment. Nat Rev Neurol 15:473–481. https://doi.org/10.1038/s41582-019-0221-1CrossRefPubMed

66.

La Regina M, Gasparyan AY, Orlandini F, Prisco D (2010) Behçet’s disease as a model of venous thrombosis. Open Cardiovasc Med J 4:71–77. https://doi.org/10.2174/1874192401004020071CrossRefPubMedPubMedCentral

67.

Pober JS, Sessa WC (2007) Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7:803–815. https://doi.org/10.1038/nri2171CrossRefPubMed

68.

Teuwen L-A, Geldhof V, Pasut A, Carmeliet P (2020) COVID-19: the vasculature unleashed. Nat Rev Immunol 20:389–391. https://doi.org/10.1038/s41577-020-0343-0CrossRefPubMedPubMedCentral

69.

Gross PL, Aird WC (2000) The endothelium and thrombosis. Semin Thromb Hemost 26:463–478. https://doi.org/10.1055/s-2000-13202CrossRefPubMed

70.

Pearson JD (2015) Plasticity of adult endothelium: how frequent and to what extent? Cardiovasc Res 108:319–320. https://doi.org/10.1093/cvr/cvv240CrossRefPubMed

71.

Rajendran P, Rengarajan T, Thangavel J et al (2013) The vascular endothelium and human diseases. Int J Biol Sci 9:1057–1069. https://doi.org/10.7150/ijbs.7502CrossRefPubMedPubMedCentral

72.

Urano T, Suzuki Y (2012) Accelerated fibrinolysis and its propagation on vascular endothelial cells by secreted and retained tPA. J Biomed Biotechnol 2012:208108. https://doi.org/10.1155/2012/208108CrossRefPubMedPubMedCentral

73.

Ye J, Zhang B, Xu J et al (2007) Molecular pathology in the lungs of severe acute respiratory syndrome patients. Am J Pathol 170:538–545. https://doi.org/10.2353/ajpath.2007.060469CrossRefPubMedPubMedCentral

74.

Hamming I, Timens W, Bulthuis MLC et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637. https://doi.org/10.1002/path.1570CrossRefPubMedPubMedCentral

75.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. https://doi.org/10.1056/NEJMoa2001017CrossRefPubMedPubMedCentral

76.

Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRefPubMedPubMedCentral

77.

Suzuki Y, Yasui H, Brzoska T, Mogami H, Urano T (2011) Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood 118:3182–3185. https://doi.org/10.1182/blood-2011-05-353912CrossRefPubMed

78.

Escher R, Breakey N, Lämmle B (2020) Severe COVID-19 infection associated with endothelial activation. Thromb Res 190:62. https://doi.org/10.1016/j.thromres.2020.04.014CrossRefPubMedPubMedCentral

79.

McGonagle D, Sharif K, O’Regan A, Bridgewood C (2020) The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 102537. https://doi.org/10.1016/j.autrev.2020.102537

80.

Roncati L, Ligabue G, Fabbiani L, Malagoli C, Gallo G, Lusenti B, Nasillo V, Manenti A, Maiorana A (2020) Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol Orlando Fla 108487:108487. https://doi.org/10.1016/j.clim.2020.108487CrossRef

81.

Semeraro N, Ammollo CT, Semeraro F, Colucci M (2015) Coagulopathy of acute Sepsis. Semin Thromb Hemost 41:650–658. https://doi.org/10.1055/s-0035-1556730CrossRefPubMed

82.

McGonagle D, O’Donnell JS, Sharif K et al (2020) Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2:e437–e445. https://doi.org/10.1016/S2665-9913(20)30121-1CrossRefPubMedPubMedCentral

83.

Maier CL, Truong AD, Auld SC et al (2020) COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet Lond. https://doi.org/10.1016/S0140-6736(20)31209-5

84.

Forconi S, Pieragalli D, Guerrini M, Galigani C, Cappelli R (1987) Primary and secondary blood hyperviscosity syndromes, and syndromes associated with blood hyperviscosity. Drugs 33(Suppl 2):19–26. https://doi.org/10.2165/00003495-198700332-00006CrossRefPubMed

85.

Bi X, Su Z, Yan H et al (2020) Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets:1–6. https://doi.org/10.1080/09537104.2020.1760230

86.

Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 58:1116–1120. https://doi.org/10.1515/cclm-2020-0188CrossRefPubMed

87.

Ranucci M, Ballotta A, Di Dedda U et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. https://doi.org/10.1111/jth.14854

88.

Bray MA, Sartain SA, Gollamudi J, Rumbaut RE (2020) MICROVASCULAR thrombosis: experimental and clinical implications. Transl Res J Lab Clin Med. https://doi.org/10.1016/j.trsl.2020.05.006

89.

Rinaldi LF, Marazzi G, Marone EM (2020) Endovascular treatment of a ruptured pararenal abdominal aortic aneurysm in a COVID-19 patient: suggestions and case report. Ann Vasc Surg 66:18–23. https://doi.org/10.1016/j.avsg.2020.05.011CrossRefPubMedPubMedCentral

90.

Shih M, Swearingen B, Rhee R (2020) Ruptured abdominal aortic aneurysm treated with endovascular repair in a patient with active COVID-19 infection during the pandemic. Ann Vasc Surg 66:14–17. https://doi.org/10.1016/j.avsg.2020.05.001CrossRefPubMedPubMedCentral

91.

Powezka K, Khan T, Narlawar R, Antoniou GA (2020) Ruptured popliteal artery aneurysm complicated with acute respiratory distress syndrome secondary to SARS-CoV-2 infection. Ann Vasc Surg 66:24–27. https://doi.org/10.1016/j.avsg.2020.05.012CrossRefPubMedPubMedCentral

92.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

93.

Verdecchia P, Cavallini C, Spanevello A, Angeli F (2020) The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 76:14–20. https://doi.org/10.1016/j.ejim.2020.04.037CrossRefPubMedPubMedCentral

94.

Fraga-Silva RA, Da Silva DG, Montecucco F et al (2012) The angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost 108:1089–1096. https://doi.org/10.1160/TH12-06-0396CrossRefPubMed

95.

Fang C, Stavrou E, Schmaier AA et al (2013) Angiotensin 1-7 and mas decrease thrombosis in Bdkrb2−/− mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 121:3023–3032. https://doi.org/10.1182/blood-2012-09-459156CrossRefPubMedPubMedCentral

96.

Fraga-Silva RA, Sorg BS, Wankhede M, deDeugd C, Jun JY, Baker MB, Li Y, Castellano RK, Katovich MJ, Raizada MK, Ferreira AJ (2010) ACE2 activation promotes antithrombotic activity. Mol Med Camb Mass 16:210–215. https://doi.org/10.2119/molmed.2009.00160CrossRefPubMedPubMedCentral

97.

Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M (1997) Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 77:1189–1195CrossRefPubMed

98.

van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G (1994) Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90:362–368. https://doi.org/10.1161/01.cir.90.1.362CrossRefPubMed

99.

Wright FL, Vogler TO, Moore EE et al (2020) Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2020.05.007

100.

Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD (2019) The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med 39:345–357. https://doi.org/10.3343/alm.2019.39.4.345CrossRefPubMedPubMedCentral

101.

Qu R, Ling Y, Zhang Y-H-Z et al (2020) Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. https://doi.org/10.1002/jmv.25767

102.

Yang A-P, Liu J-P, Tao W-Q, Li H-M (2020) The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 84:106504. https://doi.org/10.1016/j.intimp.2020.106504CrossRefPubMedPubMedCentral

103.

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood. 135:2033–2040. https://doi.org/10.1182/blood.2020006000CrossRefPubMed

104.

Becker RC (2020) COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis:1–14. https://doi.org/10.1007/s11239-020-02134-3

105.

Nagai M, Terao S, Vital SA, Rodrigues SF, Yilmaz G, Granger D (2011) Role of blood cell-associated angiotensin II type 1 receptors in the cerebral microvascular response to ischemic stroke during angiotensin-induced hypertension. Exp Transl Stroke Med 3:15. https://doi.org/10.1186/2040-7378-3-15CrossRefPubMedPubMedCentral

106.

Yamamoto K, Takeshita K, Kojima T et al (2005) Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 66:276–285. https://doi.org/10.1016/j.cardiores.2004.11.013CrossRefPubMed

107.

Fraga-Silva RA, Pinheiro SVB, Gonçalves ACC, Alenina N, Bader M, Souza Santos RA (2008) The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med 14:28–35. https://doi.org/10.2119/2007-00073.Fraga-SilvaCrossRefPubMedPubMedCentral

108.

Sodhi CP, Wohlford-Lenane C, Yamaguchi Y et al (2018) Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Phys Lung Cell Mol Phys 314:L17–L31. https://doi.org/10.1152/ajplung.00498.2016CrossRef

109.

Waldner MJ, Baethmann A, Uhl E, Lehmberg J (2012) Bradykinin-induced leukocyte- and platelet-endothelium interactions in the cerebral microcirculation. Brain Res 1448:163–169. https://doi.org/10.1016/j.brainres.2012.02.010CrossRefPubMed

110.

Afshar-Kharghan V (2017) Complement and clot. Blood 129:2214–2215. https://doi.org/10.1182/blood-2017-03-771501CrossRefPubMedPubMedCentral

111.

Foley JH, Walton BL, Aleman MM, O'Byrne AM, Lei V, Harrasser M, Foley KA, Wolberg AS, Conway EM (2016) Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 5:175–182. https://doi.org/10.1016/j.ebiom.2016.02.011CrossRefPubMedPubMedCentral

112.

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD (2020) Complement as a target in COVID-19? Nat Rev Immunol 20:343–344. https://doi.org/10.1038/s41577-020-0320-7CrossRefPubMed

113.

Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 141:1739–1741. https://doi.org/10.1161/CIRCULATIONAHA.120.047419CrossRefPubMed

114.

Diurno F, Numis FG, Porta G et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040–4047. https://doi.org/10.26355/eurrev_202004_20875CrossRefPubMed

115.

Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 214:108393. https://doi.org/10.1016/j.clim.2020.108393CrossRefPubMedPubMedCentral

116.

Iba T, Levi M, Levy JH (2020) Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 46:89–95. https://doi.org/10.1055/s-0039-1694995CrossRefPubMed

117.

Karakike E, Giamarellos-Bourboulis EJ (2019) Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 10:55. https://doi.org/10.3389/fimmu.2019.00055CrossRefPubMedPubMedCentral

118.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Coagulopathy and Antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382:e38. https://doi.org/10.1056/NEJMc2007575CrossRefPubMed

119.

Asherson RA, Cervera R (2003) Antiphospholipid antibodies and infections. Ann Rheum Dis 62:388–393. https://doi.org/10.1136/ard.62.5.388CrossRefPubMedPubMedCentral

120.

Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, del Toro-Cervera J, di Natale M, Demelo-Rodríguez P (2020) Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 192:113–115. https://doi.org/10.1016/j.thromres.2020.05.017CrossRefPubMedPubMedCentral

121.

Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL, Bardin N (2020) Anti-cardiolipin IgG autoantibodies are an independent risk factor of COVID-19 severity. Arthritis Rheum. https://doi.org/10.1002/art.41409

122.

Mehta S, Bhandari S, Mehta S (2020) Cautious interpretation of antiphospholipid antibodies in COVID-19. Clin Chim Acta Int J Clin Chem 509:166. https://doi.org/10.1016/j.cca.2020.06.024CrossRef

123.

Ayerbe L, Risco C, Ayis S (2020) The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02162-z

124.

Menezes-Rodrigues FS, Padrão Tavares JG, Pires de Oliveira M, Guzella de Carvalho R, Ruggero Errante P, Omar Taha M, Fagundes DJ, Caricati-Neto A (2020) Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients. J Thromb Haemost. https://doi.org/10.1111/jth.14902

125.

Ahmed S, Anirvan P (2020) Reply to rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19? Clin Rheumatol 39:2099–2100. https://doi.org/10.1007/s10067-020-05145-wCrossRefPubMedPubMedCentral

126.

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18:1023–1026. https://doi.org/10.1111/jth.14810CrossRefPubMed

127.

Gavioli EM, Sikorska G, Man A et al (2020) Current perspectives of anticoagulation in patients with COVID-19. J Cardiovasc Pharmacol. https://doi.org/10.1097/FJC.0000000000000861

128.

Ozolina A, Sarkele M, Sabelnikovs O, Skesters A, Jaunalksne I, Serova J, Ievins T, Bjertnaes LJ, Vanags I (2016) Activation of coagulation and fibrinolysis in acute respiratory distress syndrome: a prospective pilot study. Front Med 3:64. https://doi.org/10.3389/fmed.2016.00064CrossRef

129.

Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, Yaffe MB, Moore HB, Barrett CD (2020) Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. https://doi.org/10.1111/jth.14828

130.

Christie DB, Nemec HM, Scott AM et al (2020) Early outcomes with utilization of tissue plasminogen activator in COVID-19 associated respiratory distress: a series of five cases. J Trauma Acute Care Surg. https://doi.org/10.1097/TA.0000000000002787

131.

Choudhury R, Barrett CD, Moore HB et al (2020) Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg 15. https://doi.org/10.1186/s13017-020-00305-4

132.

Whyte CS, Morrow GB, Mitchell JL et al (2020) Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14872

133.

Vaughan DE (2011) PAI-1 antagonists: the promise and the peril. Trans Am Clin Climatol Assoc 122:312–325PubMedPubMedCentral

134.

Gong L, Proulle V, Fang C, Hong Z, Lin Z, Liu M, Xue G, Yuan C, Lin L, Furie B, Flaumenhaft R, Andreasen P, Furie B, Huang M (2016) A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med 20:1851–1860. https://doi.org/10.1111/jcmm.12875CrossRefPubMedPubMedCentral

135.

Yu B, Zhang G, Jin L et al (2017) Inhibition of PAI-1 activity by Toddalolactone as a mechanism for promoting blood circulation and removing stasis by Chinese herb Zanthoxylum nitidum var. tomentosum. Front Pharmacol 8:489. https://doi.org/10.3389/fphar.2017.00489CrossRefPubMedPubMedCentral

136.

Bernard GR, Vincent JL, Laterre PF, LaRosa S, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709. https://doi.org/10.1056/NEJM200103083441001CrossRefPubMed

137.

Ikezoe T (2015) Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care 3:1. https://doi.org/10.1186/s40560-014-0050-7CrossRefPubMedPubMedCentral

138.

Viecca M, Radovanovic D, Forleo GB, Santus P (2020) Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. https://doi.org/10.1016/j.phrs.2020.104950

139.

Thomas G (2020) Renin-angiotensin system inhibitors in COVID-19. Cleve Clin J Med. https://doi.org/10.3949/ccjm.87a.ccc009

140.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD (2020) Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653–1659. https://doi.org/10.1056/NEJMsr2005760CrossRefPubMed

141.

Zhang X, Yu J, Pan L-Y, Jiang H-Y (2020) ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacol Res 158:104927. https://doi.org/10.1016/j.phrs.2020.104927CrossRefPubMedPubMedCentral

142.

Pirola CJ, Sookoian S (2020) Estimation of RAAS-inhibitor effect on the COVID-19 outcome: a meta-analysis. J Inf Secur. https://doi.org/10.1016/j.jinf.2020.05.052

143.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN (2020) Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. N Engl J Med 382:2582. https://doi.org/10.1056/NEJMc2021225CrossRefPubMed

144.

Guo X, Zhu Y, Hong Y (2020, 1979) Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension:a meta-analysis. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.120.15572

145.

Suo Y, Zhang Z, Fu H, Zhang Y, Yuan M, Wang Y, Goudis CA, Tse G, Liu T, Li G (2018) Inhibition of renin-angiotensin axis reduces the risk of thrombus formation in the left atrial appendage in patients with hypertension complicated by atrial fibrillation. J Renin-Angiotensin Aldosterone Syst 19:19. https://doi.org/10.1177/1470320318782623CrossRef

146.

Schmaier AH (2016) A novel antithrombotic mechanism mediated by the receptors of the Kallikrein/Kinin and renin-angiotensin systems. Front Med 3:61. https://doi.org/10.3389/fmed.2016.00061CrossRef

147.

Düsing R (2016) Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Ther Adv Cardiovasc Dis 10:151–161. https://doi.org/10.1177/1753944716644130CrossRefPubMedPubMedCentral

148.

Marinšek M, Sinkovič A (2016) Ramipril and losartan exert a similar long-term effect upon markers of heart failure, endogenous fibrinolysis, and platelet aggregation in survivors of ST-elevation myocardial infarction: a single centre randomized trial. Biomed Res Int 2016:9040457–9040457. https://doi.org/10.1155/2016/9040457CrossRefPubMedPubMedCentral

149.

Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F (2020) Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2020.05.006

150.

Maglakelidze N, Manto KM, Craig TJ (2020) A review: does complement or the contact system have a role in protection or pathogenesis of COVID-19? Pulm Ther. https://doi.org/10.1007/s41030-020-00118-5

151.

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of immune therapy in coronavirus disease 2019. J Korean Med Sci 35:e176. https://doi.org/10.3346/jkms.2020.35.e176CrossRefPubMedPubMedCentral

152.

Branch DR (2019) Serologic problems associated with administration of intravenous immune globulin (IVIg). Immunohematology 35:13–15PubMed

153.

Bentley P, Rosso M, Sadnicka A, Israeli-Korn S, Laffan M, Sharma P (2012) Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure. J Clin Pharm Ther 37:286–290. https://doi.org/10.1111/j.1365-2710.2011.01287.xCrossRefPubMed

154.

Drelich DA, Bray PF, Herman JH (2012) Immunoglobulin therapy and thrombosis: coincidence or causation? Transfusion (Paris) 52:2075–2077. https://doi.org/10.1111/j.1537-2995.2012.03868.xCrossRef

155.

Valk SJ, Piechotta V, Chai KL et al (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 5:CD013600. https://doi.org/10.1002/14651858.CD013600CrossRefPubMed

156.

Bloch EM, Shoham S, Casadevall A et al (2020) Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 130:2757–2765. https://doi.org/10.1172/JCI138745CrossRefPubMedPubMedCentral

157.

Baudel JL, Vigneron C, Pras-Landre V, Joffre J, Marjot F, Ait-Oufella H, Bigé N, Maury E, Guidet B, Fain O, Mekinian A (2020) Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clin Rheumatol 39:541–546. https://doi.org/10.1007/s10067-019-04832-7CrossRefPubMed

158.

Chun S, Chung CR, Ha YE, Han TH, Ki CS, Kang ES, Park JK, Peck KR, Cho D (2016) Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome. Ann Lab Med 36:393–395. https://doi.org/10.3343/alm.2016.36.4.393CrossRefPubMedPubMedCentral

159.

Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A, Miró-Mur F (2020) Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev 102569:102569. https://doi.org/10.1016/j.autrev.2020.102569CrossRef

160.

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055–2062. https://doi.org/10.1007/s10067-020-05073-9CrossRefPubMed

161.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R (2020) The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun 111:102468. https://doi.org/10.1016/j.jaut.2020.102468CrossRefPubMedPubMedCentral

162.

Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD (2012) Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 18:1543–1555. https://doi.org/10.2174/138161212799504759CrossRefPubMed

163.

Schreiber K, Breen K, Parmar K, Rand JH, Wu XX, Hunt BJ (2018) The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatol Oxf Engl 57:120–124. https://doi.org/10.1093/rheumatology/kex378CrossRef

164.

Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11:1781–1794. https://doi.org/10.1517/17425255.2015.1076391CrossRefPubMed

165.

Deftereos S, Giannopoulos G, Vrachatis DA et al (2020) Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa033

166.

Piantoni S, Patroni A, Toniati P, Furloni R, Franceschini F, Andreoli L, Scarsi M (2020) Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. Rheumatol Oxford 59:1769–1770. https://doi.org/10.1093/rheumatology/keaa217CrossRef

167.

Demidowich AP, Levine JA, Apps R et al (2005) Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. Int J Obes 2020:1–7. https://doi.org/10.1038/s41366-020-0598-3CrossRef

168.

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4CrossRefPubMedPubMedCentral

169.

Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JW, Burmester GR, de Wit M, Falzon L, Landewé R (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:760–770. https://doi.org/10.1136/annrheumdis-2019-216653CrossRefPubMed

170.

Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M (2019) Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS One 14:e0220178. https://doi.org/10.1371/journal.pone.0220178CrossRefPubMedPubMedCentral

171.

Brito CA, Paiva JG, Pimentel FN, Guimarães RS, Moreira MR (2020) COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis:annrheumdis-2020-218171. https://doi.org/10.1136/annrheumdis-2020-218171

172.

Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sørensen HT (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173:743–752. https://doi.org/10.1001/jamainternmed.2013.122CrossRefPubMed

173.

Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020-217871CrossRefPubMed

Titel: Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
verfasst von: Sakir Ahmed
Olena Zimba
Armen Yuri Gasparyan
Publikationsdatum: 11.07.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Clinical Rheumatology / Ausgabe 9/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05275-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Syndemic and syndemogenesis of low back pain in Latin-American population: a network and cluster analysis

A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab

Human immunodeficiency virus infection (HIV)–associated rheumatic manifestations in thepre- and post-HAART eras

Microangiopathy and forearm arterial blood flow in systemic sclerosis: a controlled study

Sclerochoroidal calcifications associated with early-onset calcium pyrophosphate deposition disease

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin